NPPB and hydrops fetalis: The HF patients with SGLT2i treatment (group 4) showed a significant decrease in NT-proBNP levels (from 1819.6 [547.3–5695.4] to 782.1 pg/mL [181.5–2954.0]; p = 0.008), but other groups did not (p for interaction = 0.028 between group 4 vs. 3).